Frost & Sullivan Independent Equity Research
DNA Biomedical Solutions Ltd. Entera filed an updated F-1 for its Nasdaq IPO; BeamMed retained its sales pace, with a key focus on penetrating the US market; preparations for pre-IND (505(b)(2) submission; Target price remains unchanged.
Company: DNA Biomedical Solutions Ltd.
Report type: Q1-2018 Update
Published on: 10 June, 2018